Clinical Trials

(NYSE:TEVA) TEL AVIV, Israel, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced plans to present data from the completed phase 3 SOLARIS trial at the 2025 Psych Congress Annual Meeting, taking place from September 17 – 21, 2025, in San Diego, California.

(NASDAQ:NBIX) Additional Data from SAVITRI™ Study Expand on Top-Line Results Announced in April 2024 SAVITRI Poster Presentation Chosen as Finalist for Psych Congress Poster Awards SAN DIEGO, Sept. 16, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present...

(NASDAQ:KURA) Analyst/Investor event showcases opportunities for KO-2806 (darlifarnib) in combination with PI3Kα inhibitors, KRAS inhibitors and antiangiogenic tyrosine kinase inhibitors (TKIs)

BEND, Ore. & SAN FRANCISCO--(BUSINESS WIRE)--Bendable Therapy and Osmind will unveil the first real-world evidence study of legal psilocybin services in the US.

OVERLAND PARK, Kan.--(BUSINESS WIRE)-- #Asthma--Dr. Vince Clinical Research announces first dosing in atopic dermatitis patients with Enveda’s first-in-class investigational drug ENV-294.

(NASDAQ:ENVB) CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced that it has received a written response from the U.S. Food and Drug Administration (FDA) to its request for a Pre-Investigational New Drug (pre-IND) Type B meeting for its lead program, EB-003. In its response, the FDA indicated that the questions f

(NASDAQ:CBTX) CAMBRIDGE, Mass.--(BUSINESS WIRE)--Crossbow Therapeutics, Inc., a biotechnology company focused on advancing T-Bolt™ therapies, a novel class of antibody therapeutics, today announced dosing of the first participant in its CROSSCHECK-001 Phase 1 clinical trial of CBX-250, a first-in-class, potent, and specific T-cell engager (TCE) for the treatment of myeloid malignancies. “Patients with relapsed or refractory myeloid malignancies urgently need new treatment options, and CBX-250 offers a novel

(NASDAQ:TNDM) SAN DIEGO--(BUSINESS WIRE)---- $TNDM #diabetes--Tandem Diabetes Care® (NASDAQ: TNDM), a global insulin delivery and diabetes technology company, today announced the publication of a study, "Adults with Type 2 Diabetes Benefit from Automated Insulin Delivery Irrespective of C-peptide Level," in the American Diabetes Association’s Diabetes Care. The study, a sub-analysis from the 2IQP randomized, controlled trial, found that the Control-IQ+ automated insulin delivery (AID) system was beneficial for adults with insul

(NASDAQ:LTRN) DALLAS--(BUSINESS WIRE)--Clinical Trial Results, LP-184

(NYSE:IQV) RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, has been honored with the WCG Pinnacle Award for Site Relationships in Professionalism and Communication. The award recognizes IQVIA’s commitment to building strong, collaborative partnerships with clinical trial sites worldwide. The award is based on feedback from over 12,000 par

HOUSTON--(BUSINESS WIRE)-- #DoD--Enrollment has opened at UTHealth San Antonio for a 51-participant, FDA-authorized double-blind placebo-controlled Phase II clinical trial to evaluate if intravenously infused Hope Biosciences autologous, adipose-derived mesenchymal stem cells (HB-adMSCs) affect brain structure, neurocognitive and functional outcomes, and/or neuroinflammation after traumatic brain injury (TBI) in adults. The Department of Defense (DoD)-funded trial is now underway in Houston and San An

(NYSE:ALC) GENEVA--(BUSINESS WIRE)--Alcon Announces New Time and Motion Study Results Supporting Superior Efficiency* for Cataract and Vitreoretinal Surgery with UNITY VCS

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Novocuff, Inc., a clinical-stage, maternal health medical device company, today announced approval from the U.S. Food and Drug Administration of its Investigational Device Exemption (IDE) application for the RETAIN Study. The study is a randomized, multicenter, pivotal trial evaluating the Novocuff Cervical Control System™ (CCS). The RETAIN study evaluates the safety and effectiveness of the Novocuff CCS, a medical device intended to retain amniotic fluid

(NYSE:ALC) GENEVA--(BUSINESS WIRE)--Alcon Announces New Time and Motion Study Results Supporting Superior Efficiency* for Cataract and Vitreoretinal Surgery with UNITY VCS

(TSCA) CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #ClinicalTrials--Tasca Therapeutics has dosed the first patient in its Phase 1/2 dose escalation and expansion study of CP-383 in advanced solid tumors.

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Apollo Therapeutics, the portfolio biopharmaceutical company, today announces positive results from its 32-week CHAMELEON phase 2a clinical trial of camoteskimab (an anti-IL-18 mAb that degrades IL-18 through an antibody recycling mechanism) in patients with moderate to severe atopic dermatitis (AD) conducted in the US and Canada (NCT06436183). The double-blind, randomized, placebo-controlled trial (n=62) demonstrated clinically meaningful efficacy,

NEW YORK--(BUSINESS WIRE)-- #AIinHealthcare--AccurKardia, an innovator in ECG-based diagnostics technology, has announced the initiation of a multicenter clinical pilot of AK+ GuardTM, an FDA Breakthrough Device Designated AI-powered technology that enables the detection of hyperkalemia using Lead I ECG. The three-arm prospective pilot study will evaluate more than 150 patients across inpatient, outpatient and home settings in the U.S. Hyperkalemia, or an excess of serum potassium in the blood, is a common condi

SOUTHBOROUGH, Mass.--(BUSINESS WIRE)-- #Veristat--Veristat, a global clinical research organization (CRO) and consultancy specializing in complex studies, announces its successful partnership with Cook MyoSite to support the DigniFI Study, a two-stage, randomized, controlled Phase III trial comparing the safety and efficacy of iltamiocel with placebo in the treatment of female participants with chronic fecal incontinence (FI) and a history of obstetric anal sphincter injury (OASI). Veristat successfully su

CHAPEL HILL, N.C.--(BUSINESS WIRE)--Areteia Therapeutics, Inc. (“Areteia”) today announced positive results from the Phase III EXHALE-4 efficacy and safety study of dexpramipexole as an add-on oral therapy in participants with eosinophilic asthma. “More than half of people with asthma have the eosinophilic subtype, yet there remains a profound need for easily administered oral treatment options that can help address their symptoms, which are often severe,” said Ian Pavord, MA, DM, Professor of

(COV) MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced the publication of results from a peer-reviewed clinical study investigating the use of Covalon’s VALGuard® Vascular Access Line Guard in the Journal of the Association for Vascular Access (JAVA). Conducted at the Children’s Hospital at Montefiore, a nationally ranked U.S. pediatric hospital, the study, titled “Evaluat